Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

scientific article published on 5 August 2017

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.TRCI.2017.07.001
P932PMC publication ID5651439
P698PubMed publication ID29067350

P50authorMaria C CarrilloQ51070685
Ricardo S OsorioQ57001600
Steven E. ArnoldQ64157128
Zahinoor IsmailQ87798445
Constantine G. LyketsosQ91213781
David S. MillerQ118299151
Sonia Ancoli-IsraelQ37322997
Clive BallardQ40279915
Krista L LanctôtQ42725631
Jiska Cohen-MansfieldQ44627653
P2093author name stringAndrew Satlin
Lisa J Bain
Paul B Rosenberg
David Steffens
Joan Amatniek
James A Hendrix
Brendon Boot
Pierre Tariot
Erik Musiek
Heidi Jurgens
P2860cites workLocus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's diseaseQ48599203
Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET studyQ48669455
Family, Alzheimer's disease and negative symptomsQ48684723
Apathy and depression in mild Alzheimer's disease: a cross-sectional study using diagnostic criteriaQ48690050
Neuropathologic and neurochemical correlates of psychosis in primary dementiaQ48717187
Alz-50 immunoreactivity in the hypothalamus of the normal and Alzheimer human and the rat.Q48738385
Reliability and validity of the apathy evaluation scaleQ48866734
Substantia nigra tangles are related to gait impairment in older personsQ50279058
CORDIAL: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: a multicenter, randomized, controlled trial.Q50606263
The incremental direct costs associated with behavioral symptoms in AD.Q50711680
The measurement of psychosis in dementia: a comparison of assessment tools.Q51749556
Psychotic symptoms in dementia and the rate of cognitive decline.Q52041977
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.Q52056472
Associations of psychotic symptoms in dementia sufferers.Q53213623
Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype.Q53216036
The stress and psychological morbidity of the Alzheimer patient caregiver.Q53230330
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.Q53274559
Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome.Q53338995
Assessment of Agitation in Older AdultsQ60298805
Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and HQ61902867
Major and minor depression in Alzheimer's disease: prevalence and impactQ74108883
The epidemiology of psychosis in dementiaQ78792553
Pharmacotherapies for sleep disturbances in Alzheimer's diseaseQ24197895
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycleQ24644961
The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disordersQ26823480
Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?Q26827219
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the futureQ26864905
Assessment and management of behavioral and psychological symptoms of dementiaQ28088782
Sleep drives metabolite clearance from the adult brainQ29620065
Decoupling of the brain's default mode network during deep sleepQ30484161
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trialsQ33153605
Measurement of inappropriate behavior associated with dementia.Q33646486
Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosisQ33668661
Sertraline for the treatment of depression in Alzheimer diseaseQ33741090
Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based studyQ33753288
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trialQ33863623
Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer diseaseQ34090664
Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County StudyQ34100750
Neuroimaging of delusions in Alzheimer's disease.Q34306435
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trialQ34370011
Regional cerebral blood flow changes as a function of delta and spindle activity during slow wave sleep in humans.Q34427637
Research Domain Criteria: toward future psychiatric nosologiesQ34476922
Amnestic mild cognitive impairment and incident dementia and Alzheimer's disease in geriatric depressionQ34490382
The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysisQ34500657
Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's diseaseQ34708307
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definitionQ34992886
Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression studyQ35004787
The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive declineQ35015551
"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysisQ35106233
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trialQ35109857
The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design ApproachQ35111772
Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer's disease: results of a randomized, controlled trialQ35171044
Early neurone loss in Alzheimer's disease: cortical or subcortical?Q35176873
Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates.Q35218921
Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort studyQ35240761
Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression StudyQ35561413
Sleep-disordered breathing advances cognitive decline in the elderlyQ35611633
Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older womenQ35630404
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.Q35630897
Neuropsychiatric symptoms in Alzheimer's diseaseQ35823575
The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia.Q35858684
Magnitude and causes of bias among family caregivers rating Alzheimer disease patientsQ35899036
Citalopram for agitation in Alzheimer's disease: design and methodsQ35905635
The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive ImpairmentQ36149767
The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease.Q36191996
Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairmentQ36385255
Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older womenQ36694340
Sleep quality and preclinical Alzheimer diseaseQ36913338
Cognitive effects of treating obstructive sleep apnea in Alzheimer's disease: a randomized controlled studyQ36978103
Predictors of progression to severe Alzheimer's disease in an incidence sampleQ37218809
β-amyloid dynamics in human plasmaQ37254727
Modulation of the brain's functional network architecture in the transition from wake to sleepQ37263065
Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration.Q37383982
Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluidQ37432083
Continuous positive airway pressure deepens sleep in patients with Alzheimer's disease and obstructive sleep apneaQ37439204
Late-life depression, mild cognitive impairment, and dementia: possible continuum?Q37682019
Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacyQ37788481
Neurobiology of delusions in Alzheimer's disease.Q37853072
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trialQ37901878
Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomesQ38053311
Efficacy of nonpharmacologic interventions for agitation in advanced dementia: a randomized, placebo-controlled trialQ38462691
Rethinking Psychosis in Dementia: An Analysis of Antecedents and ExplanationsQ38806621
Monoaminergic neuropathology in Alzheimer's diseaseQ38809649
Apathy associated with neurocognitive disorders: Recent progress and future directions.Q38846813
AVP-786 for the treatment of agitation in dementia of the Alzheimer's typeQ39034436
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementiaQ39605807
Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties.Q40502916
Quality of life in dementia patients in long-term careQ40777926
Dementia in institutionalized elderly: relation to sleep apneaQ41180232
Grey matter atrophy in mild cognitive impairment / early Alzheimer disease associated with delusions: a voxel-based morphometry studyQ41475094
Pathological alterations in the amygdala in Alzheimer's diseaseQ41767135
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia PopulationsQ42381174
The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's DiseaseQ42470207
Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's diseaseQ42492635
Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert.Q42492680
Depression in Alzheimer's disease: the effect of serotonin receptor gene variationQ44411869
Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosisQ44450158
Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.Q44513123
Behavioral symptoms in mild cognitive impairmentQ44840318
Poor sleep quality impairs cognitive performance in older adultsQ45767463
Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patientsQ46040803
Nonpharmacologic treatment of behavioral disorders in dementiaQ46240025
Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementiaQ46304586
Sleep-disordered breathing and cognition in older womenQ46447954
The persistence of neuropsychiatric symptoms in dementia: the Cache County Study.Q47272225
The meanings of delusions in dementia: a preliminary studyQ47584510
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA TrialQ47641602
Self-reported sleep disturbance is associated with Alzheimer's disease risk in men.Q48013471
Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.Q48022782
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's diseaseQ48150612
Sleep disturbance is associated with incident dementia and mortalityQ48162950
Variations in connectivity in the sensorimotor and default-mode networks during the first nocturnal sleep cycle.Q48232326
Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disordersQ48298818
Development of the brain's default mode network from wakefulness to slow wave sleepQ48316407
Development of a large-scale functional brain network during human non-rapid eye movement sleepQ48343413
Differences in brain metabolism associated with agitation and depression in Alzheimer's diseaseQ48419321
P433issue3
P921main subjectAlzheimer's diseaseQ11081
P304page(s)440-449
P577publication date2017-08-05
P1433published inAlzheimer's & dementia (New York, N. Y.)Q27726239
P1476titleNeuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
P478volume3

Reverse relations

cites work (P2860)
Q92377056A human memory circuit derived from brain lesions causing amnesia
Q90248276A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia
Q92210508Behavioral Disturbances in Dementia and Beyond: Time for a New Conceptual Frame?
Q50199042Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
Q92128709Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice
Q99592757Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition
Q91410950Dementia in Down syndrome: unique insights for Alzheimer disease research
Q90124631Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults
Q64282137Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study
Q58077250Extracellular Vesicles in Psychiatry Research in the Context of RDoC Criteria
Q91781569Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1
Q52608019Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.
Q92051615Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Q93016317Multilevel Impacts of Iron in the Brain: The Cross Talk between Neurophysiological Mechanisms, Cognition, and Social Behavior
Q64868646Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease
Q64910410Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease.
Q91715548Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach
Q92101808Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA
Q58124331New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis
Q99544929Remodeling of projections from ventral hippocampus to prefrontal cortex in Alzheimer's mice
Q93391029Reproducibility of brain MRS in older healthy adults at 7T
Q49962834Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia
Q90638313Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions
Q64252307The Effects of Acupuncture on Glutamatergic Neurotransmission in Depression, Anxiety, Schizophrenia, and Alzheimer's Disease: A Review of the Literature
Q90704728The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer's Disease: Current Management and Future Directions
Q92535704The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer's Disease
Q57495494The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease
Q88931208The influence of the individual neuropsychiatric symptoms of people with Alzheimer disease on family caregiver distress-A longitudinal ALSOVA study
Q91620137The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents
Q64101560Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers
Q102209096Trajectories and risk factors of dementia progression: a memory clinic cohort followed up to 3 years from diagnosis
Q91326936Unmet needs in community-living persons with dementia are common, often non-medical and related to patient and caregiver characteristics

Search more.